R
Roland E. Schmieder
Researcher at University of Erlangen-Nuremberg
Publications - 780
Citations - 85811
Roland E. Schmieder is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Blood pressure & Essential hypertension. The author has an hindex of 97, co-authored 717 publications receiving 78138 citations. Previous affiliations of Roland E. Schmieder include Complutense University of Madrid & University of Regensburg.
Papers
More filters
Journal ArticleDOI
Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks.
Stefan John,Christian Delles,Johannes Jacobi,Markus P. Schlaich,Markus P. Schneider,Gerd Schmitz,Roland E. Schmieder +6 more
TL;DR: Short-term lipid-lowering therapy with cerivastatin can improve endothelium-dependent vasodilation and NO bioavailability after two weeks in patients with hypercholesterolemia.
Journal ArticleDOI
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study
Roland E. Schmieder,Frank Wagner,Michael Mayr,Christian Delles,Christian Ott,Christian Keicher,Maja Hrabak-Paar,Maja Hrabak-Paar,Tobias Heye,Solveig Aichner,Yasser Khder,Denise Yates,Diego Albrecht,Thomas Langenickel,Patrick Freyhardt,Rolf Janka,Jens Bremerich +16 more
TL;DR: The finding that LV mass index decrease might be to some extent independent of SBP suggests that the effect of the dual-acting agent may go beyond those due to its BP-lowering ability.
Journal ArticleDOI
Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
Kristina Striepe,Agnes Jumar,Christian Ott,Marina V. Karg,Markus P. Schneider,Dennis Kannenkeril,Roland E. Schmieder +6 more
TL;DR: Treatment with empagliflozin reduced the primary combined cardiovascular end point (3P-MACE [3-point major adverse cardiovascular event]), as well as secondary end points of hospitalization because of heart failure, cardiovascular morbidity, total mortality, and renal end points.
Journal ArticleDOI
Hypertension and the heart.
Roland E. Schmieder,FH Messerli +1 more
TL;DR: Various aspects of LV hypertrophy including its prevalence, determinants, prognosis and regression are discussed in this article.
Journal ArticleDOI
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
Christian Ott,Agnes Jumar,Kristina Striepe,Stefanie Friedrich,Marina V. Karg,Peter Bramlage,Roland E. Schmieder +6 more
TL;DR: Six weeks of dapagliflozin treatment resulted in improvements in diabetes control, including blood glucose and insulin resistance, and reduced office and 24-h ambulatory blood pressure values.